Zynerba halts development of THC prodrug ZYN001
The Pennsylvania-based cannabinoid-based drug developer reported that the drug, which is delivered via a transdermal patch, could not achieve the target blood levels of 5 to 15ng/ml THC
The US Food and Drug Administration (FDA) has granted orphan drug designation (ODD) to Papillon Therapeutics’ PPL-001, aimed at treating Friedreich's ataxia, a rare neurodegenerative disorder.
The regulator has accepted the application for a type II variation to the marketing authorization for Rubracato include maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian
These therapeutic antibodies include ‘blood-brain barrier (BBB)’ penetrating bispecific antibodies (BsAb) (VEGF/undisclosed BBB target BsAb, undisclosed target/undisclosed BBB target BsAb); immune cell engaging bispecific antibodies (4-1BB/undisclosed target BsAb,